Loading clinical trials...
Loading clinical trials...
Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis
Conditions
Interventions
mycophenolate mofetil (Cellcept)
human interferon beta 1a (Rebif)
Locations
1
United States
The Ohio State University Multiple Sclerosis Center
Columbus, Ohio, United States
Start Date
August 1, 2006
Primary Completion Date
May 1, 2012
Completion Date
May 1, 2012
Last Updated
November 15, 2012
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
Aaron Boster
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions